Synaptic proteasome is inhibited in Alzheimer’s disease models and associates with memory impairment in mice
Felipe C. Ribeiro, Danielle Cozachenco, Luana Heimfarth, Juliana T.S. Fortuna, Guilherme B. de Freitas, Jorge M. de Sousa, Soniza Vieira Alves‐Leon, Renata Elaine Paraízo Leite, Cláudia Kimie Suemoto, Lea T. Grinberg, Fernanda G. De Felice, Mychael V. Lourenco, Sérgio T. Ferreira
Abstract
The proteasome plays key roles in synaptic plasticity and memory by regulating protein turnover, quality control, and elimination of oxidized/misfolded proteins. Here, we investigate proteasome function and localization at synapses in Alzheimer's disease (AD) post-mortem brain tissue and in experimental models. We found a marked increase in ubiquitinylated proteins in post-mortem AD hippocampi compared to controls. Using several experimental models, we show that amyloid-β oligomers (AβOs) inhibit synaptic proteasome activity and trigger a reduction in synaptic proteasome content. We further show proteasome inhibition specifically in hippocampal synaptic fractions derived from APPswePS1ΔE9 mice. Reduced synaptic proteasome activity instigated by AβOs is corrected by treatment with rolipram, a phosphodiesterase-4 inhibitor, in mice. Results further show that dynein inhibition blocks AβO-induced reduction in dendritic proteasome content in hippocampal neurons. Finally, proteasome inhibition induces AD-like pathological features, including reactive oxygen species and dendritic spine loss in hippocampal neurons, inhibition of hippocampal mRNA translation, and memory impairment in mice. Results suggest that proteasome inhibition may contribute to synaptic and memory deficits in AD.